Document and Entity Information	12 Months Ended
Document and Entity Information	Dec. 31, 2018 shares
Document and Entity Information [Abstract]
Entity Registrant Name	Gamida Cell Ltd.
Entity Central Index Key	0001600847
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	No
Entity Current Reporting Status	Yes
Entity Shell Company	false
Entity Filer Category	Non-accelerated Filer
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Common Stock, Shares Outstanding	24,930,736
Document Type	20-F
Amendment Flag	false
Document Period End Date	Dec. 31, 2018
Document Fiscal Year Focus	2018
Document Fiscal Period Focus	FY

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
CURRENT ASSETS:
Cash and cash equivalents	$ 40,272	$ 21,325
Available-for-sale financial assets	20,417	14,758
Short term deposits	0	5,000
Prepaid expenses and other current assets	1,502	2,539
Total current assets	62,191	43,622
NON-CURRENT ASSETS:
Property and equipment, net	2,311	940
Other assets	662	360
Total non-current assets	2,973	1,300
Total assets	65,164	44,922
CURRENT LIABILITIES:
Trade payables	1,985	2,390
Employees and payroll accruals	2,888	1,517
Accrued expenses and other payables	1,832	669
Total current liabilities	6,705	4,576
NON-CURRENT LIABILITIES:
Liabilities presented at fair value	24,049	10,300
Employee benefit liabilities, net	183	200
Liability to Israel Innovation Authority (IIA)	9,540	6,890
Total non-current liabilities	33,772	17,390
CONTINGENT LIABILITIES AND COMMITMENTS
SHAREHOLDERS' EQUITY:
Share premium	193,953	139,311
Capital reserve due to actuarial loss	(77)	(79)
Available for sale reserve	(43)	(34)
Accumulated deficit	(169,213)	(116,282)
Total shareholders' equity	24,687	22,956
Total liabilities and shareholders' equity	65,164	44,922
Ordinary Shares [Member]
SHAREHOLDERS' EQUITY:
Share capital	67	2
Total shareholders' equity	67	2
Preferred Shares [Member]
SHAREHOLDERS' EQUITY:
Share capital	0	38
Total shareholders' equity	$ 0	$ 38

CONSOLIDATED STATEMENTS OF FINANCIAL POSITION (Parenthetical) - ₪ / shares	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
Ordinary Shares [Member]
SHAREHOLDERS' EQUITY:
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Authorized (in shares)	100,000,000	23,277,000
Issued (in shares)	24,930,736	689,898
Outstanding (in shares)	24,930,736	689,898	689,898	689,898
Preferred Shares [Member]
SHAREHOLDERS' EQUITY:
Par value (in sheqel per share)		₪ 0.01
Authorized (in shares)	0	16,723,000
Issued (in shares)	0	14,154,743
Outstanding (in shares)	0	14,154,743	9,880,380	9,880,380

CONSOLIDATED STATEMENTS OF COMPREHENSIVE LOSS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Operating expenses:
Research and development expenses, net	$ 22,045	$ 15,018	$ 19,095
General and administrative expenses	11,599	4,472	4,614
Operating loss	33,644	19,490	23,709
Financial expenses	20,259	718	155
Financial income	(1,042)	(1,197)	(1,193)
Loss before taxes on income	52,861	19,011
Taxes on income	70	0	0
Net Loss	52,931	19,011	22,671
Items that will be reclassified subsequently to profit or loss:
Actuarial net loss of defined benefit plans	(2)	35	20
Changes in the fair value of available for sale financial assets	9	34	0
Total comprehensive loss	$ 52,938	$ 19,080	$ 22,691
Net loss per share:
Basic and diluted net loss per share (in dollars per share)	$ 10.53	$ 27.56	$ 32.86
Weighted average number of ordinary shares used in computing basic and diluted net loss per share (in shares)	5,025,213	689,898	689,898

CONSOLIDATED STATEMENTS OF CHANGES IN EQUITY - USD ($) $ in Thousands	Total	Ordinary Shares [Member]	Preferred Shares [Member]	Share Premium [Member]	Available for Sale Reserve Amount [Member]	Capital Reserve due to Actuarial Losses [Member]	Accumulated Deficit [member]
Balance at Dec. 31, 2015	$ 27,812	$ 2	$ 26	$ 102,408	$ 0	$ (24)	$ (74,600)
Balance (in shares) at Dec. 31, 2015		689,898	9,880,380
Changes in equity [abstract]
Net loss	(22,671)	$ 0	$ 0	0	0	0	(22,671)
Other comprehensive loss	(20)	0	0	0	0	(20)	0
Total comprehensive loss	(22,691)	0	0	0	0	(20)	(22,671)
Share-based compensation	5,842	0	0	5,842	0	0	0
Balance at Dec. 31, 2016	10,963	$ 2	$ 26	108,250	0	(44)	(97,271)
Balance (in shares) at Dec. 31, 2016		689,898	9,880,380
Changes in equity [abstract]
Net loss	(19,011)	$ 0	$ 0	0	0	0	(19,011)
Other comprehensive loss	(69)	0	0	0	(34)	(35)	0
Total comprehensive loss	(19,080)	0	0	0	(34)	(35)	(19,011)
Issuance of series F-1 preferred shares, net of issuance costs	28,865		$ 12	28,853	0	0	0
Issuance of series F-1 preferred shares, net of issuance costs (in shares)			4,274,363
Share-based compensation	2,208	0	$ 0	2,208	0	0	0
Balance at Dec. 31, 2017	22,956	$ 2	$ 38	139,311	(34)	(79)	(116,282)
Balance (in shares) at Dec. 31, 2017		689,898	14,154,743
Changes in equity [abstract]
Net loss	(52,931)	$ 0	$ 0	0	0	0	(52,931)
Other comprehensive loss	(7)	0	0	0	(9)	2	0
Total comprehensive loss	(52,938)	0	0	0	(9)	2	(52,931)
Issuance of additional preferred shares following Anti-dilution Protection	0	$ 0	$ 8	(8)	0	0	0
Issuance of additional preferred shares following Anti-dilution Protection (in shares)		0	3,134,546
Exercise of options	2	$ 0	$ 0	2	0	0	0
Exercise of options (in shares)		9,692	0
Conversion of preferred shares	0	$ 46	$ (46)	0	0	0	0
Conversion of preferred shares (in shares)		17,289,289	(17,289,289)
Issuance of ordinary shares in initial public offering, net of issuance expenses	47,241	$ 18	$ 0	47,223	0	0	0
Issuance of ordinary shares in initial public offering, net of issuance expenses (in shares)		6,648,368	0
Exercise of warrants	3,851	$ 1	$ 0	3,850	0	0	0
Exercise of warrants (in shares)		293,489	0
Share-based compensation	3,575	$ 0	$ 0	3,575	0	0	0
Balance at Dec. 31, 2018	$ 24,687	$ 67	$ 0	$ 193,953	$ (43)	$ (77)	$ (169,213)
Balance (in shares) at Dec. 31, 2018		24,930,736	0

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Cash flows from operating activities:
Net loss	$ (52,931)	$ (19,011)	$ (22,671)
Adjustments to the profit or loss items:
Depreciation	269	162	124
Financial income, net	(858)	(330)	92
Cost of share-based compensation	3,575	2,208	5,842
Change in employee benefit liabilities, net	(15)	26	28
Amortization of premium on available-for-sale financial assets	272	28	0
Revaluation of financial derivatives	17,600	(1,061)	(805)
Revaluation of liability to IIA	2,037	631	0
Other	0	0	37
Adjustments to reconcile profit (loss)	22,880	1,664	5,318
Changes in asset and liability items:
Decrease (Increase) in other receivables, prepaid expenses and other current assets	942	(2,210)	13
(Decrease) Increase in trade payables	(405)	1,464	297
Decrease in related parties	0	0	148
Change in liability to IIA	0	0	4,030
Increase in accrued expenses and other payables and employees and payroll accruals	2,296	1,214	131
Cash flows from (used in) operations	2,833	468	4,619
Cash received during the year for:
Interest received	792	330	144
Net cash used in operating activities	(26,426)	(16,549)	(12,590)
Cash flows from investing activities:
Purchase of property and equipment	(1,645)	(402)	(284)
Purchase of available-for-sale financial assets	(10,905)	(14,820)	0
Proceeds from (investment in) bank deposits	5,000	(5,000)	0
Investment in restricted bank deposits	(150)	0	0
Proceed from sale of available-for-sale financial assets	4,949	0	0
Proceeds from liquidation of joint venture and other assets	0	0	595
Net cash (used in) provided by investing activities	(2,751)	(20,222)	311
Cash flows from financing activities:
Receipt of grants from the IIA	612	272	1,688
Proceeds from issuance of financial derivatives	0	10,900	0
Proceeds from initial public offering, net	47,479	0	0
Exercise of options	2	0	0
Proceeds from issuance of shares, net	0	28,865	0
Net cash provided by financing activities	48,093	40,037	1,688
Exchange differences on balances of cash and cash equivalents	31	0	(92)
Increase (decrease) in cash and cash equivalents	18,947	3,266	(10,683)
Cash and cash equivalents at beginning of year	21,325	18,059	28,742
Cash and cash equivalents at end of year	40,272	21,325	18,059
Significant non-cash transactions:
IIA liability for grants to be received	0	269	0
Exercise of warrants liabilities to equity	3,851	0	0
Issuance expenses on credit	$ 238	$ 0	$ 0

GENERAL

12 Months Ended

Dec. 31, 2018

GENERAL [Abstract]

GENERAL

NOTE 1:-

GENERAL

Gamida Cell Ltd. (the “Company”), founded in 1998, is a clinical-stage biopharmaceutical company that develops novel curative treatments for orphan indications, including hematological malignancies and rare genetic diseases using stem cells and natural killer (NK) cells.

On October 30, 2018, the Company closed an Initial Public Offering (“IPO”) of its ordinary shares on the Nasdaq, under the symbol “GMDA” which resulted in the sale of 6,250,000 ordinary shares at a public offering price of $8 per share, before underwriting discounts. The underwriters purchased 398,368 additional shares at a public offering price of $8 per share. The Company received net proceeds from the IPO of approximately $47,241 (net of issuance costs and underwriting discounts of approximately $5,947). Upon the closing of the IPO, all of the Company’s outstanding preferred shares automatically converted into 17,289,289 ordinary shares.

The Company uses its proprietary platform NAM technology to expand in culture, highly functional cells derived from umbilical cord blood or peripheral blood, while enhancing the potential therapeutic efficacy of these cells.

The Company’s lead product candidate, NiCord®, is currently being developed in a pivotal Phase 3 clinical study to treat patients with various hematologic malignancies, such as leukemias and lymphomas, who are indicated to receive a donor-derived hematopoietic stem cell transplant (bone marrow transplant). Bone marrow transplantation with a graft derived from a matched donor is currently the standard-of-care treatment for many of these patients, but there is a significant unmet need for patients who cannot find a fully matched donor. NiCord is designed as a universal graft that addresses the limitations found in other sources of donor cells.

NiCord was granted Breakthrough Therapy designation from the FDA and Orphan Drug designation in the US and in Europe.

At the 2017 American Society of Hematology meeting, the Company presented final results from the Phase 1/2 trial evaluating NiCord. The study met its primary endpoint, demonstrating rapid neutrophil engraftment with manageable side effects.

In addition to hematologic malignancies, the Company is pursuing the development of NiCord for the treatment of bone marrow failure disorders. NiCord is currently being evaluated in a Phase 1/2 clinical trial sponsored by the National Institutes of Health in patients with severe aplastic anemia, a rare, life-threatening hematological disorder.

Beyond NiCord, the Company develops another product candidate, NAM-NK, for innate immunotherapy of expanded NK cells, to be used in combination with standard-of-care therapeutic antibodies. NK cells have potent anti-tumor properties and have the advantage over other oncology cell therapies of not requiring genetic matching, potentially enabling NK cells to serve as a universal donor-based therapy when combined with certain antibodies. A Phase 1 investigator-initiated study to treat patients with B-cell lymphoma and multiple myeloma is enrolling patients.

The Company is devoting substantially all of its efforts toward research and development activities. In the course of such activities, the Company has sustained operating losses and expects such losses to continue in the foreseeable future. The Company’s accumulated deficits as of December 31, 2018 amounted to $169,213 and negative cash flows from operating activities for years ended December 31, 2018 amounted to $26,426. The Company requires additional financing in order to continue to fund its current operations and pay existing and future liabilities.

These conditions raise substantial doubt about the Company’s ability to continue as a going concern. The consolidated financial statements do not include any adjustments to the carrying amounts and classifications of assets and liabilities that would result if the Company was unable to continue as a going concern.

Definitions:

In these financial statements:

The Company

Gamida Cell Ltd. and its Subsidiary

Subsidiary

Gamida Cell Inc. Incorporated in 2000 and intended to focus on sales and marketing upon product approval

Related Parties

As defined in IAS 24

Dollar

U.S. dollar

SIGNIFICANT ACCOUNTING POLICIES

12 Months Ended

Dec. 31, 2018

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

SIGNIFICANT ACCOUNTING POLICIES

NOTE 2:-

SIGNIFICANT ACCOUNTING POLICIES

The following accounting policies have been applied consistently in the financial statements for all periods presented, unless otherwise stated.

Basis of presentation of the financial statements:

These consolidated financial statements have been prepared in accordance with International Financial Reporting Standards (“IFRS”) as issued by the International Accounting Standards Board (“IASB”).

The consolidated financial statements have been prepared on a cost basis, except for available-for-sale financial assets and financial liabilities that have been measured at fair value through profit or loss. The Company has elected to present profit or loss items using the function of expense method.

The operating cycle of the Company is one year.

Consolidated financial statements:

The consolidated financial statements comprise the financial statements of the Company and its Subsidiary.

The financial statements of the Company and its Subsidiary are prepared as of the same dates and periods. The consolidated financial statements are prepared using uniform accounting policies by all companies in the group. Significant intra-group balances, transactions and gains or losses resulting from intra-group are eliminated in full in the consolidated financial statements.

Functional currency, presentation currency and foreign currency:

Functional currency and presentation currency:

The presentation currency of the financial statements is the U.S. dollar.

The functional currency is the currency that best reflects the economic environment in which the Company and its Subsidiary operate and conduct their transactions. Most of the Company costs are incurred in U.S. dollars. In addition, the Company's financing activities are incurred in U.S. dollars. The Company’s management believes that the functional currency of the Company is the U.S. dollar.

Transactions, assets and liabilities in foreign currency:

Transactions denominated in foreign currency are recorded upon initial recognition at the exchange rate at the date of the transaction. After initial recognition, monetary assets and liabilities denominated in foreign currency are translated at the end of each reporting period into the functional currency at the exchange rate at that date. Exchange rate differences are recognized in profit or loss. Non-monetary assets and liabilities measured at cost in foreign currency are translated at the exchange rate at the date of the transaction. Non-monetary assets and liabilities denominated in foreign currency and measured at fair value are translated into the functional currency using the exchange rate prevailing at the date when the fair value was determined.

Cash equivalents:

Cash equivalents are considered as highly liquid investments, including unrestricted short-term bank deposits with an original maturity of three months or less from the date of investment or with a maturity of more than three months, but which are redeemable on demand without penalty and which form part of the Company’s cash management.

Short-term deposits and restricted deposits:

Short-term bank deposits are deposits with an original maturity of more than three months from the date of investment and which do not meet the definition of cash equivalents. The deposits are presented according to their terms of deposit.

Restricted deposit is primarily invested in highly liquid deposits. Restricted deposit amounted to $150 and $0 as of December 31, 2018 and 2017, respectively and is included in prepaid expenses and other current assets on the statements of financial position.

Property and equipment:

Property, plant and equipment are measured at cost, including directly attributable costs, less accumulated depreciation, accumulated impairment losses and any related investment grants and excluding day-to-day servicing expenses.

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%

Machinery		15
Office furniture and equipment		6 - 33
Leasehold improvements		(*)

(*)

Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.

Research and development costs:

Research expenditures are recognized in profit or loss when incurred. An intangible asset arising from a development project or from the development phase of an internal project is recognized if the Company can demonstrate: the technical feasibility of completing the intangible asset so that it will be available for use or sale; the Company’s intention to complete the intangible asset and use or sell it; the Company’s ability to use or sell the intangible asset; how the intangible asset will generate future economic benefits; the availability of adequate technical, financial and other resources to complete the intangible asset; and the Company’s ability to measure reliably the expenditure attributable to the intangible asset during its development. Since the Company's development projects are often subject to regulatory approval procedures and other uncertainties, the conditions for the capitalization of costs incurred before receipt of approvals are not normally satisfied and, therefore, development expenditures are recognized in profit or loss when incurred.

Impairment of non-financial assets:

The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.

If the carrying amount of non-financial assets exceeds their recoverable amount, the assets are reduced to their recoverable amount. The recoverable amount is the higher of fair value less costs of sale and value in use. The recoverable amount of an asset that does not generate independent cash flows is determined for the cash-generating unit to which the asset belongs. Impairment losses are recognized in profit or loss.

An impairment loss of an asset is reversed only if there have been changes in the estimates used to determine the asset’s recoverable amount since the last impairment loss was recognized. Reversal of an impairment loss, as above, shall not be increased above the lower of the carrying amount that would have been determined (net of depreciation or amortization) had no impairment loss been recognized for the asset in prior years, and its recoverable amount.

During the years ended December 31, 2018, 2017 and 2016, the Company did not recognize any impairment of non-financial assets.

Government investment grants:

Government grants are recognized when there is reasonable assurance that the grants will be received and the Company will comply with the related conditions.

Government grants received from Israel Innovation Authority (“IIA”) (formerly, the Office of the Chief Scientist in Israel (“OCS”)) are recognized upon receipt as a liability if future economic benefits are expected from the project that will result in royalty-bearing sales. If no such economic benefits are expected, the grants are recognized as a reduction of the related research and development expenses. In that event, the royalty obligation is treated as contingent liability in accordance with IAS 37.

At the end of each reporting period, the Company evaluates, based on its best estimate of future sales, whether there is reasonable assurance that the liability recognized, in whole or in part, will not be repaid (since the Company will not be required to pay royalties). If there is such reasonable assurance, the appropriate amount of the liability is derecognized and recorded in profit or loss as a revaluation of research and development expenses.

If the estimate of future sales indicates that there is no such reasonable assurance, the appropriate amount of the liability that reflects expected future royalty payments is recognized with a corresponding adjustment to financial expenses or income. As of December 31, 2018 and 2017, the Company determined that future economic benefits are expected from its research and development project and recorded a liability for its entire contingent obligation to IIA.

Grants received from the IIA which are recognized as a liability are accounted for as forgivable loans, in accordance with IAS 20 (Revised). Accordingly, when the liability for the loan is first recognized, it is measured at fair value using a discount rate that reflects a market rate of interest, which in the Company’s case was determined to be 28% and 25% for 2018 and 2017, respectively. The difference between the amount of the grants received and the fair value of the liability is accounted for upon recognition of the liability as a government grant and recognized as a reduction of research and development expenses.

For the years ended December 31, 2018, 2017 and 2016 no royalties were paid with respect to grants received from the IIA. Payments will be treated as a reduction of the liability.

Grants in the amount of $2,425, $2,948 and $4,264 were approved during 2018, 2017 and 2016, respectively. Grant receivable amounted to $0 and $1,578 as of December 31, 2018 and 2017, respectively, and is included in prepaid expenses and other current assets on the statements of financial position.

Provisions:

A provision in accordance with IAS 37 is recognized when the Company has a present obligation (legal or constructive) as a result of a past event, it is probable that an outflow of resources embodying economic benefits will be required to settle the obligation and a reliable estimate can be made of the amount of the obligation.

Operating leases:

Lease agreements are classified as an operating lease if they do not transfer substantially all the risks and benefits incidental to ownership of the leased asset. Operating lease payments are recognized as an expense in profit or loss on a straight-line basis over the lease term.

Share-based payment transactions:

The Company’s employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions.

Equity-settled transactions:

The cost of equity-settled transactions with employees is measured at the fair value of the equity instruments granted at grant date. The fair value is determined using an acceptable option pricing model.

With respect to other service providers, the cost of the transactions is measured at the fair value of the goods or services received as consideration for equity instruments. In cases where the fair value of the goods or services received as consideration of equity instruments cannot be measured, it is measured by reference to the fair value of the equity instruments granted.

The cost of equity-settled transactions is recognized in profit or loss, together with a corresponding increase in equity, during the period which the performance and/or service conditions are to be satisfied, ending on the date on which the relevant employee becomes fully entitled to the award.

No expense is recognized for awards that do not ultimately vest, except for awards where vesting is conditional upon a market condition, which are treated as vested irrespective of whether the market condition is satisfied, provided that all other vesting conditions are satisfied.

Deferred tax:

Deferred tax is provided using the liability method on temporary differences between the tax bases of assets and liabilities and their carrying amounts for financial reporting purposes at the reporting date.

Deferred tax assets are recognized for all deductible temporary differences. Deferred tax assets are recognized to the extent that it is probable that taxable profit will be available against which the deductible temporary differences and unused tax losses can be utilized.

Unrecognized deferred tax assets are re-assessed at each reporting date and are recognized to the extent that it has become probable that future taxable profits will allow the deferred tax asset to be recovered.

Employee benefit liabilities:

The Company has several employee benefit plans:

Short-term employee benefits:

Short-term employee benefits are benefits that are expected to be settled entirely before twelve months after the end of the annual reporting period in which the employees render the related services. These benefits include salaries, paid annual leave, paid sick leave, recreation and social security contributions and are recognized as expenses as the services are rendered.

Post-employment benefits:

The plans are normally financed by contributions to insurance companies and classified as defined benefit plans.

The Company operates a defined benefit plan in respect of severance pay pursuant to the Severance Pay Law, 1963 (the “Law”). According to the Law, employees are entitled to severance pay upon dismissal or retirement. The liability for termination of employment is measured using the projected unit credit method. The amounts are presented based on discounted expected future cash flows using a discount rate determined by reference to yields on Government bonds.

In respect of its severance pay obligation to certain of its employees, the Company makes current deposits in pension funds and insurance companies (the “Plan Assets”). Plan Assets comprise assets held by a long-term employee benefit fund or qualifying insurance policies. Plan Assets are not available to the Company’s own creditors and cannot be returned directly to the Company.

Actuarial gains and losses are recognized in other comprehensive income or (loss) retrospectively in the period in which they occur.

Initial adoption of IFRS 9, “Financial Instruments”:

In July 2014, the IASB issued the final and complete version of IFRS 9, “Financial Instruments” (“the new Standard”), which replaces IAS 39, “Financial Instruments: Recognition and Measurement”. The new Standard mainly focuses on the classification and measurement of financial assets and it applies to all assets within the scope of IAS 39.

The new Standard has been applied for the first time in these financial statements retrospectively without restatement of comparative data.

There is no material effect of the initial adoption of the new Standard on the Company’s financial statements.

Financial instruments:

As described in Note 2p regarding the initial adoption of IFRS 9, “Financial Instruments” (“the Standard”), the Company elected to adopt the provisions of the Standard retrospectively without restatement of comparative data.

The accounting policy for financial instruments applied until December 31, 2017, is as follows:

Investment in marketable securities:

Financial assets within the scope of IAS 39 are initially recognized at fair value plus directly attributable transaction costs, except for financial assets measured at fair value through profit or loss in respect of which transaction costs are recorded in profit or loss.

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

Financial assets at fair value through profit or loss

Held-to-maturity investments

Loans and receivables

Available-for-sale financial assets

The Company classifies all of its marketable securities as available-for-sale. Available-for-sale financial assets are (non-derivative) financial assets that are designated as available for sale or are not classified in any of the three preceding categories. After initial recognition, available-for-sale financial assets are measured at fair value. Gains or losses from fair value adjustments, except for interest, exchange rate differences that relate to debt instruments and dividends from an equity instrument, are recognized in other comprehensive income. When the investment is disposed of or in case of impairment, the other comprehensive income (loss) is transferred to profit or loss.

Marketable securities as of December 31, 2017 and 2018 includes corporate and government debentures with no significant premium or discount. The investment in marketable securities which are classified as available-for-sale is considered Level 2 measurement.

Financial liabilities:

Financial liabilities are recognized initially at fair value and, in the case of loans and borrowings and payables net of directly attribute transaction costs. The Company’s financial liabilities include trade and other payables and warrants to shareholders.

Warrants to shareholders can be excercised into a variable number of shares and therefore such warrants are recorded as a financial liability and are measured at each balance sheet date at their fair value. Gains or losses are recognized in profit or loss.

Derecognition:

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

Offsetting of financial instruments:

Financial assets and financial liabilities are offset and the net amount is reported in the statements of financial position if there is a currently enforceable legal right to offset the recognized amounts and there is an intention to settle on a net basis, to realize the assets and settle the liabilities simultaneously.

Fair value:

Fair value is the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. The fair value of an asset or a liability is measured using the assumptions that market participants would use when pricing the asset or liability, assuming that market participants act in their economic best interest.

The Company uses valuation techniques that are appropriate in the circumstances and for which sufficient data are available to measure fair value, maximizing the use of relevant observable inputs and minimizing the use of unobservable inputs.

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy.

The carrying amounts of cash and cash equivalents, available-for-sale financial assets, other receivables, short-term deposits and other current assets, trade payables and accrued expenses and other payables approximate their fair value due to the short-term maturity of such instruments. Regarding fair value of the liability to IIA, refer to note 2j above.

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

12 Months Ended

Dec. 31, 2018

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS [Abstract]

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

NOTE 3:-

SIGNIFICANT ACCOUNTING JUDGMENTS, ESTIMATES AND ASSUPMTIONS USED IN THE PREPARATION OF THE FINANCIAL STATEMENTS

The key assumptions made in the financial statements concerning uncertainties at the end of the reporting period and the critical estimates computed by the Company that may result in a material adjustment to the carrying amounts of assets and liabilities within the next financial year are discussed below.

Government grants:

Government grants received from the IIA at the Ministry of Industry, Trade and Labor are recognized as a liability if future economic benefits are expected from the research and development activity that will result in royalty-bearing sales. There is uncertainty regarding the estimated future cash flows and the estimated discount rate used to measure the amortized cost of the liability.

Determining the fair value of an unquoted financial liabilities:

The fair value of unquoted financial liabilities in Level 3 of the fair value hierarchy is determined using valuation techniques including projected cash flows discounted at current rates applicable for items with similar terms and risk characteristics. Changes in estimated projected cash flows and estimated discount rates, after consideration of risk factors such as liquidity risk, credit risk and volatility, are liable to affect the fair value of these liabilities.

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

12 Months Ended

Dec. 31, 2018

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION [Abstract]

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

NOTE 4:-

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION

IFRS 16, “Leases”:

In January 2016, the IASB issued IFRS 16, “Leases” (“the new Lease Standard”). According to the new Lease Standard, a lease is a contract, or part of a contract, that conveys the right to use an asset for a period of time in exchange for consideration.

The effects of the adoption of the new Lease Standard are as follows:

According to the new Lease Standard, lessees are required to recognize all leases in the statement of financial position (excluding certain exceptions, see below). Lessees will recognize a liability for lease payments with a corresponding right-of-use asset, similar to the accounting treatment for finance leases under the existing standard, IAS 17, “Leases”. Lessees will also recognize interest expense and depreciation expense separately.

Variable lease payments that are not dependent on changes in the Consumer Price Index (“CPI”) or interest rates, but are based on performance or use are recognized as an expense by the lessees as incurred and recognized as income by the lessors as earned.

In the event of a change in variable lease payments that are CPI-linked, lessees are required to remeasure the lease liability and record the effect of the remeasurement as an adjustment to the carrying amount of the right-of-use asset.

The accounting treatment by lessors remains substantially unchanged from the existing standard, namely classification of a lease as a finance lease or an operating lease.

The new Lease Standard includes two exceptions which allow lessees to account for leases based on the existing accounting treatment for operating leases - leases for which the underlying asset is of low financial value and short-term leases (up to one year).

The new Lease Standard is effective for annual periods beginning on or after January 1, 2019.

The Company will apply the modified retrospective approach upon the initial adoption of the new Lease Standard by measuring the right-of-use asset at an amount equal to the lease liability, as measured on the transition date.

The Company has a number of lease contracts, mainly leases of an office building and a production plant (see also Note 9). In assessing the impact of the new Lease Standard on the financial statements, the Company evaluated the following matters:

Options to extend the lease - according to the new Lease Standard, the non-cancellable period of a lease includes periods that are covered by options to extend the lease if the lessee is reasonably certain to exercise the option.

Separation of lease components - according to the new Lease Standard, all lease components within a contract should be accounted for separately from non-lease components. A lessee is allowed a practical expedient according to which it can elect, by class of underlying asset, not to separate non-lease components from lease components, and instead account for them as a single lease component.

Incremental interest rate - the Company estimates the incremental interest rate to be used for measuring the lease liability and right-of-use asset on the date of initial adoption of the new Lease Standard, based on the lease term and nature of the leased asset.

The Company estimated that the effect of the initial adoption of the new Lease Standard as of January 1, 2019, is expected to result in an increase in the Company’s total assets and liabilities in the amount to $7,523 and no impact on equity.

Moreover, the effect of the initial adoption of the new Lease Standard in 2019 is expected to result in a decrease in the Company’s lease expenses of $1,940 and an increase in the Company’s depreciation and finance expenses of $1,928 and $94, respectively. The total effect of the initial adoption of the new Lease Standard in 2019 is expected to result in a decrease of $12 in operating loss and an increase of $82 in loss before income taxes.

PROPERTY AND EQUIPMENT, NET

12 Months Ended

Dec. 31, 2018

PROPERTY AND EQUIPMENT, NET [Abstract]

PROPERTY AND EQUIPMENT, NET

NOTE 6:-

PROPERTY AND EQUIPMENT, NET

Composition and movement:

2018:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2018	$	2,181	$	396	$	992	$	47	$	3,616
Additions		973		139		107		421		1,640

Balance at December 31, 2018		3,154		535		1,099		468		5,256

Accumulated depreciation:

Balance at January 1, 2018		1,558		308		810		-		2,676
Depreciation		195		37		37		-		269

Balance at December 31, 2018		1,753		345		847		-		2,945

Property and equipment, net at December 31, 2018	$	1,401	$	190	$	252	$	468	$	2,311

2017:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2017	$	1,902	$	369	$	943	$	-	$	3,214
Additions		279		27		49		47		402

Balance at December 31, 2017		2,181		396		992		47		3,616

Accumulated depreciation:

Balance at January 1, 2017		1,433		292		789		-		2,514
Depreciation		125		16		21		-		162

Balance at December 31, 2017		1,558		308		810		-		2,676

Property and equipment, net at December 31, 2017	$	623	$	88	$	182	$	47	$	940

LIABILITIES PRESENTED AT FAIR VALUE

12 Months Ended

Dec. 31, 2018

LIABILITIES PRESENTED AT FAIR VALUE [Abstract]

LIABILITIES PRESENTED AT FAIR VALUE

NOTE 8:-

LIABILITIES PRESENTED AT FAIR VALUE

Warrants to purchase Preferred F-2 shares:

On June 18, 2017 the Company signed a Series F Preferred Share Purchase Agreement (“SPA”) with existing and new investors. According to the SPA and upon the closing that occurred on July 9, 2017 the Company issued 4,274,363 Preferred F-1 shares, nominal value NIS 0.01 each, at $9.44 per share, accompanied by the issuance of warrants to purchase 2,564,619 Preferred F-2 shares, nominal value NIS 0.01, with an exercise price of $11.33 per share, in exchange for an aggregate proceeds of $40,350. The issuance costs in the amount of $585 associated with the equity transaction have been charged directly to the consolidated statements of changes in equity and the issuance costs associated with the issuance of the warrants in the amount of $216 have been charged directly to the statement of comprehensive loss.

According to the SPA, the warrants to purchase Preferred F-2 Shares are subject to conversion ratio to be adjusted as defined in the SPA and to non-standard anti-dilution protection provisions and cashless exercise mechanism and therefore accounted for as a financial liability which was measured at fair value through profit or loss.

Upon the closing of the IPO as described in note 1b, 2,564,619 warrants to purchase Preferred F-2 shares were automatically converted into warrants to purchase 4,323,978 ordinary shares, nominal value NIS 0.01, with an exercise price of $6.72 per share with an expiration until earlier of July 3, 2022 or a Deemed Liquidation event as described in the Company’s articles of association (the "AOA").

In December 2018, the Company issued a total of 293,489 ordinary shares pursuant to the cashless exercise of 607,044 warrants.

The Company measured the fair value of the warrants by using Black and Shoultz simulation model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected time until liquidation. Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The expected time until liquidation is the period in which liquidation event will occurred subject to the Company’s expectations. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares

Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value

Balance at January 1, 2016	$	1,266		$	-		$	1,266

Revaluation of financial derivatives		(805	)		-			(805	)

Balance at December 31, 2016		461			-			461

Proceeds from issue of financial derivatives		-			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		-			10,300			10,300

Exercise of warrants		-			(3,851	)		(3,851	)

Revaluation of financial derivatives		-			17,600			17,600

Balance at December 31, 2018	$	-		$	24,049		$	24,049

Description of significant unobservable inputs to valuation:

	December 31,
	2018		2017
	Preferred F-2 shares		Preferred F-2 shares
Sensitivity to changes in inputs:
Gain (loss) from change:
10% increase in volatility	$	-	$	720
10% decrease in volatility	$	-	$	(750	)

Gain (loss) from change:
1% increase in discount rate	$	-	$	(1,040	)
1% decrease in discount rate	$	-	$	(1,290	)

CONTINGENT LIABILITIES AND COMMITMENTS

12 Months Ended

Dec. 31, 2018

CONTINGENT LIABILITIES AND COMMITMENTS [Abstract]

CONTINGENT LIABILITIES AND COMMITMENTS

NOTE 9:-

CONTINGENT LIABILITIES AND COMMITMENTS

The Company has entered into commercial real estate lease agreements which consist of the office building and production plant. The leases are under non-cancellable terms and mature over 1-9 years. In December 2017, the Company signed a lease agreement for a production plant which will be effective upon fulfillment of the suspending condition as described in the lease agreement.

The future minimum lease fees payable as of December 31, 2018 are as follows:


First year	$	1,803
Second through fifth years		2,522
After fifth year		2,395

	$	6,720

The Company rents vehicles under an operating lease agreement, for a fixed monthly fee of $13. The leases are under non-cancellable terms and mature over 1-3 years.

The Company is obligated to pay royalties to the Government of Israel through the IIA at the rates of 3% to 4% on sales proceeds from products developed through the grants received from the IIA. The maximum amount of royalties payable to the Government of Israel is limited to 100% of the grants received, linked to the dollar and bearing interest at the LIBOR rate. The obligation to pay these royalties is contingent on actual sales of the products and in the absence of such sales, no payment is required. The Company expects to incur sales that will trigger payments of royalties starting in 2020. As of December 31, 2018, the Company’s aggregate contingent obligations for payments to the IIA, based on royalty-bearing participation received or accrued amounted to $34,197 (including interest of $4,916).

SHAREHOLDERS' EQUITY

12 Months Ended

Dec. 31, 2018

SHAREHOLDERS' EQUITY [Abstract]

SHAREHOLDERS' EQUITY

NOTE 10:-

SHAREHOLDERS’ EQUITY

Composition of share capital:

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares

Ordinary share of NIS 0.01 par value		100,000,000		24,930,736		22,007,000		549,990
Ordinary B share of NIS 0.01 par value		-		-		140,000		139,908
Ordinary C share of NIS 0.01 par value		-		-		1,130,000		-

		100,000,000		24,930,736		23,277,000		689,898

Series Preferred A share of NIS 0.01 par value		-		-		600,000		600,000
Series Preferred B share of NIS 0.01 par value		-		-		1,454,000		1,453,846
Series Preferred C share of NIS 0.01 par value		-		-		2,828,000		2,827,430
Series Preferred D share of NIS 0.01 par value		-		-		3,405,000		3,404,314
Series Preferred E1 share of NIS 0.01 par value		-		-		572,000		571,478
Series Preferred E2 share of NIS 0.01 par value		-		-		1,024,000		1,023,312
Series Preferred F1 share of NIS 0.01 par value		-		-		4,275,000		4,274,363
Series Preferred F2 share of NIS 0.01 par value		-		-		2,565,000		-

		-		-		16,723,000		14,154,743

Rights attached to the shares:

Ordinary shares:

Subject to our current AOA, the holders of ordinary shares have the right to receive notices to attend and vote in general meetings of the Company’s shareholders, and the right to share in dividends and other distributions and upon liquidation.

Preferred shares:

All issued and outstanding preferred shares were converted to ordinary shares upon the IPO.

SHARE-BASED PAYMENT

12 Months Ended

Dec. 31, 2018

SHARE-BASED PAYMENT [Abstract]

SHARE-BASED PAYMENT

NOTE 11:-

SHARE-BASED PAYMENT

On November 23, 2014, the Company’s Board of Directors approved, subject to the approval of the shareholders, the creation of a new class of shares of the Company, Ordinary C shares, nominal value NIS 0.01 each and to classify 1,500,000 ordinary shares for such class, 1,152,044 out of which for allocation to the Company’s employees under the new amended 2014 Israel Share Option Plan (“2014 Plan”). The exercise price of the options granted under the plans may not be less than the nominal value of the shares into which the options are exercised. The options vest primarily over three years. Any options, which are forfeited or not exercised before expiration, become available for future grants.

There are no cash settlement alternatives. On December 29, 2014, the Company’s shareholders meeting ratified and approved the aforesaid decisions.

On January 23, 2017 the Company’s Board of Directors approved the Company’s 2017 Share Incentive Plan (the “2017 Plan”), and the subsequent grant of options to the Company’s employees, officers and directors. Pursuant to the Plan, the Company initially reserved for issuance 312,867 ordinary shares, nominal value NIS 0.01 each. Contemporaneously, the Company’s Board of Directors approved the termination of the Company’s 2014 Plan and the extension of the exercise period of the outstanding options to Ordinary C shares to expire on January 2020 instead of January 2018. There was no material impact on the financial statements, with respect to the Company’s 2014 plan extension. On February 28, 2017 the Company’s shareholders approved the 2017 Plan.

On June 26, 2017 and on December 28, 2017 the Company’s Board of Directors approved the reservation of additional 463,384 and 559,764 ordinary shares, respectively, for issuance under the 2017 Plan (totaling, including previous plans, an aggregate of 1,338,015 ordinary shares).

The Company estimates the fair value of stock options granted using the Binominal option-pricing model. The option-pricing model requires a number of assumptions, of which the most significant are the expected stock price volatility and the expected option term.

Expected volatility was calculated based upon historical volatilities of similar entities in the related sector index. The expected term of the options granted is derived from output of the option valuation model and represents the period of time that options granted are expected to be outstanding. The risk-free interest rate is based on the yield from U.S. treasury bonds with an equivalent term. The Company has historically not paid dividends and has no foreseeable plans to pay dividends.

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016

Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Based on the above inputs, the fair value of the options was determined at $3.64-$5.85 at the grant date.

Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD

Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		-		-
Exercised during the period		9,692		0.25		-		-
Forfeited during the year		9,692		0.25		-		-

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

As of December 31, 2018, there are $4,103 of total unrecognized company cost related to non-vested share based compensation that are expected to be recognized over a period of up to 4 years.

TAXES ON INCOME

12 Months Ended

Dec. 31, 2018

TAXES ON INCOME [Abstract]

TAXES ON INCOME

NOTE 12:-

TAXES ON INCOME

Tax rates applicable to the income of the Company:

Corporate Tax rates:

Taxable income of the Israeli parent is subject to the Israeli corporate tax at the rate of 25% in 2016, 24% in 2017 and 23% in 2018.

Non-Israeli subsidiaries are taxed according to the tax laws in their respective countries of residence.

Income subject to tax benefits under the Law for the Encouragement of Capital Investments, 1959 (the “Investment Law”):

The Investment Law provides tax benefits for Israeli companies meeting certain requirements and criteria. The Investment Law has undergone certain amendments and reforms in recent years.

The Israeli parliament enacted a reform to the Investment Law, effective January 2011. According to the reform, a flat rate tax applies to companies eligible for the “Preferred Enterprise” status. In order to be eligible for Preferred Enterprise status, a company must meet minimum requirements to establish that it contributes to the country’s economic growth and is a competitive factor for the gross domestic product.

The Company’s Israeli operations elected “Preferred Enterprise” status, starting in 2017.

Benefits granted to a Preferred Enterprise include reduced tax rates. In peripheral regions (Development Area A) the reduced tax rate was 9% in 2016. As part of Economic Efficiency Law (Legislative Amendments for Accomplishment of Budgetary Targets for Budget Years 2017-2018), 5777-2016, the tax rate for Area A will be 7.5% in 2017 onwards. In other regions the tax rate is 16%. Preferred Enterprises in peripheral regions will be eligible for Investment Center grants, as well as the applicable reduced tax rates.

The Law for the Encouragement of Industry (Taxation), 1969:

The Company has the status of an “industrial company”, under this law. According to this status and by virtue of regulations published thereunder, the Company is entitled to claim a deduction of accelerated depreciation on equipment used in industrial activities, as determined in the regulations issued under the Inflationary Law. The Company is also entitled to amortize a patent or a patent or knowhow usage right that are used in the enterprise’s development or promotion, to deduct listed share issuance expenses and to file consolidated financial statements under certain conditions.

Net operating losses carryforward:

The Company has net operating losses and capital loss for tax purposes as of December 31, 2018, in the amount of $120,000 and $500, respectively, which may be carried forward and offset against taxable income in the future for an indefinite period.

Final tax assessments:

The Company’s tax assessments through the 2012 tax year are considered final.

Deferred taxes:

The Company did not recognize deferred tax assets in the Company’s consolidated financial statements for the years ended December 31, 2018 and 2017 for carryforward losses and other temporary differences because their utilization in the foreseeable future is not probable.

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

12 Months Ended

Dec. 31, 2018

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA [Abstract]

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

NOTE 13:-

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA

Research and development expenses, net:

	Year ended December 31,
	2018			2017			2016

Salaries and social benefits	$	5,016		$	3,795		$	2,774
Share-based payment		705			1,362			3,195
Subcontractors		12,695			9,617			8,150
Materials		3,610			1,677			2,232
Rent and maintenance		758			486			364
Travel and trade shows		728			346			507
Depreciation		195			142			124
Other		239			-			61
Less royalty bearing grants		(1,901	)		(2,407	)		(4,030	)
Reversal of grants received in prior years to related liability		-			-			5,718

Total research and development expenses, net	$	22,045		$	15,018		$	19,095

General and administrative expenses:

	Year ended December 31,
	2018		2017		2016

Salaries and social benefits	$	4,788	$	1,870	$	924
Share-based payment		2,870		846		2,647
Professional services		2,818		1,467		843
Rent and maintenance		1,065		83		138
Other		58		206		62

Total general and administrative expenses	$	11,599	$	4,472	$	4,614

Finance expenses:

	Year ended December 31,
	2018		2017		2016

Revaluation of IIA liability	$	2,037	$	631	$	-
Revaluation of liabilities at fair value		17,600		-		-
Bank charges, interest expense and other fees		68		54		23
Foreign currency translation adjustments		554		33		132

Total finance expenses	$	20,259	$	718	$	155

Finance income:

	Year ended December 31,
	2018		2017		2016

Interest income	$	877	$	330	$	163
Revaluation of liabilities at fair value		-		845		805
Foreign currency translation adjustments	$	165		22		225

Total finance income	$	1,042	$	1,197	$	1,193

SIGNIFICANT ACCOUNTING POLICIES (Policies)

12 Months Ended

Dec. 31, 2018

SIGNIFICANT ACCOUNTING POLICIES [Abstract]

Basis of presentation of the financial statements

Basis of presentation of the financial statements:

The operating cycle of the Company is one year.

Consolidated financial statements

Consolidated financial statements:

The consolidated financial statements comprise the financial statements of the Company and its Subsidiary.

Functional currency, presentation currency and foreign currency

Functional currency, presentation currency and foreign currency:

Functional currency and presentation currency:

The presentation currency of the financial statements is the U.S. dollar.

Transactions, assets and liabilities in foreign currency:

Cash equivalents

Cash equivalents:

Short-term deposits and restricted deposits

Short-term deposits and restricted deposits:

Property and equipment

Property and equipment:

Depreciation is calculated on a straight-line basis over the useful life of the assets at annual rates as follows:

	%

Machinery		15
Office furniture and equipment		6 - 33
Leasehold improvements		(*)

(*)

The useful life, depreciation method and residual value of an asset are reviewed at least each year-end and any changes are accounted for prospectively as a change in accounting estimate.

An item of property and equipment is derecognized upon disposal or when no future economic benefits are expected from its use or disposal.

Research and development costs

Research and development costs:

Impairment of non-financial assets

Impairment of non-financial assets:

The Company evaluates the need to record an impairment of the carrying amount of non-financial assets whenever events or changes in circumstances indicate that the carrying amount is not recoverable.

During the years ended December 31, 2018, 2017 and 2016, the Company did not recognize any impairment of non-financial assets.

Government investment grants

Government investment grants:

Government grants are recognized when there is reasonable assurance that the grants will be received and the Company will comply with the related conditions.

For the years ended December 31, 2018, 2017 and 2016 no royalties were paid with respect to grants received from the IIA. Payments will be treated as a reduction of the liability.

Provisions

Provisions:

Operating leases

Operating leases:

Share-based payment transactions

Share-based payment transactions:

The Company’s employees and other service providers are entitled to remuneration in the form of equity-settled share-based payment transactions.

Equity-settled transactions:

Deferred tax

Deferred tax:

Employee benefit liabilities

Employee benefit liabilities:

The Company has several employee benefit plans:

Short-term employee benefits:

Post-employment benefits:

The plans are normally financed by contributions to insurance companies and classified as defined benefit plans.

Actuarial gains and losses are recognized in other comprehensive income or (loss) retrospectively in the period in which they occur.

Initial adoption of IFRS 9, "Financial Instruments"

Initial adoption of IFRS 9, “Financial Instruments”:

The new Standard has been applied for the first time in these financial statements retrospectively without restatement of comparative data.

There is no material effect of the initial adoption of the new Standard on the Company’s financial statements.

Financial instruments

Financial instruments:

The accounting policy for financial instruments applied until December 31, 2017, is as follows:

Investment in marketable securities:

After initial recognition, the accounting treatment of financial assets is based on their classification as follows:

Financial assets at fair value through profit or loss

Held-to-maturity investments

Loans and receivables

Available-for-sale financial assets

Financial liabilities:

Derecognition:

A financial liability is derecognized when the obligation under the liability is discharged or cancelled, or expires.

Offsetting of financial instruments:

Fair value:

All assets and liabilities for which fair value is measured or disclosed in the financial statements are categorized within the fair value hierarchy.

PROPERTY AND EQUIPMENT, NET (Tables)

12 Months Ended

Dec. 31, 2018

PROPERTY AND EQUIPMENT, NET [Abstract]

Property and Equipment, Net

Composition and movement:

2018:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2018	$	2,181	$	396	$	992	$	47	$	3,616
Additions		973		139		107		421		1,640

Balance at December 31, 2018		3,154		535		1,099		468		5,256

Accumulated depreciation:

Balance at January 1, 2018		1,558		308		810		-		2,676
Depreciation		195		37		37		-		269

Balance at December 31, 2018		1,753		345		847		-		2,945

Property and equipment, net at December 31, 2018	$	1,401	$	190	$	252	$	468	$	2,311

2017:

	Machinery		Office furniture and equipment		Leasehold improvements		Project in process		Total
Cost:

Balance at January 1, 2017	$	1,902	$	369	$	943	$	-	$	3,214
Additions		279		27		49		47		402

Balance at December 31, 2017		2,181		396		992		47		3,616

Accumulated depreciation:

Balance at January 1, 2017		1,433		292		789		-		2,514
Depreciation		125		16		21		-		162

Balance at December 31, 2017		1,558		308		810		-		2,676

Property and equipment, net at December 31, 2017	$	623	$	88	$	182	$	47	$	940

LIABILITIES PRESENTED AT FAIR VALUE (Tables)

12 Months Ended

Dec. 31, 2018

LIABILITIES PRESENTED AT FAIR VALUE [Abstract]

Warrants to Purchase Preferred Shares

Warrants to purchase Company’s shares:

	December 31,
	2018			2017
	Ordinary shares			Preferred F-2 shares

Risk-free interest rate		2.5	%		1.5	%
Expected volatility		80	%		90	%
Expected life (in years)		3.5			4.5
Expected dividend yield		0			0

Changes in the Fair Value of Warrants

Changes in the fair value of warrants classified as Level 3 in the fair value hierarchy:

	Fair value of warrants E-2			Fair value of Warrants to purchase Ordinary shares			Total warrants presented at fair value

Balance at January 1, 2016	$	1,266		$	-		$	1,266

Revaluation of financial derivatives		(805	)		-			(805	)

Balance at December 31, 2016		461			-			461

Proceeds from issue of financial derivatives		-			10,900			10,900

Revaluation of financial derivatives		(461	)		(600	)		(1,061	)

Balance at December 31, 2017		-			10,300			10,300

Exercise of warrants		-			(3,851	)		(3,851	)

Revaluation of financial derivatives		-			17,600			17,600

Balance at December 31, 2018	$	-		$	24,049		$	24,049

Description of Significant Unobservable Inputs to Valuation

Description of significant unobservable inputs to valuation:

	December 31,
	2018		2017
	Preferred F-2 shares		Preferred F-2 shares
Sensitivity to changes in inputs:
Gain (loss) from change:
10% increase in volatility	$	-	$	720
10% decrease in volatility	$	-	$	(750	)

Gain (loss) from change:
1% increase in discount rate	$	-	$	(1,040	)
1% decrease in discount rate	$	-	$	(1,290	)

CONTINGENT LIABILITIES AND COMMITMENTS (Tables)

12 Months Ended

Dec. 31, 2018

CONTINGENT LIABILITIES AND COMMITMENTS [Abstract]

Future Minimum Lease Fees Payable

The future minimum lease fees payable as of December 31, 2018 are as follows:


First year	$	1,803
Second through fifth years		2,522
After fifth year		2,395

	$	6,720

SHAREHOLDERS' EQUITY (Tables)

12 Months Ended

Dec. 31, 2018

SHAREHOLDERS' EQUITY [Abstract]

Composition of Share Capital

Composition of share capital:

	December 31,
	2018				2017
	Authorized		Issued and outstanding		Authorized		Issued and outstanding
	Number of shares

Ordinary share of NIS 0.01 par value		100,000,000		24,930,736		22,007,000		549,990
Ordinary B share of NIS 0.01 par value		-		-		140,000		139,908
Ordinary C share of NIS 0.01 par value		-		-		1,130,000		-

		100,000,000		24,930,736		23,277,000		689,898

Series Preferred A share of NIS 0.01 par value		-		-		600,000		600,000
Series Preferred B share of NIS 0.01 par value		-		-		1,454,000		1,453,846
Series Preferred C share of NIS 0.01 par value		-		-		2,828,000		2,827,430
Series Preferred D share of NIS 0.01 par value		-		-		3,405,000		3,404,314
Series Preferred E1 share of NIS 0.01 par value		-		-		572,000		571,478
Series Preferred E2 share of NIS 0.01 par value		-		-		1,024,000		1,023,312
Series Preferred F1 share of NIS 0.01 par value		-		-		4,275,000		4,274,363
Series Preferred F2 share of NIS 0.01 par value		-		-		2,565,000		-

		-		-		16,723,000		14,154,743

SHARE-BASED PAYMENT (Tables)

12 Months Ended

Dec. 31, 2018

SHARE-BASED PAYMENT [Abstract]

Fair Value Measurement of Equity-Settled Share Options

The following table lists the inputs to the binomial model used for the fair value measurement of equity-settled share options for the above plan for years 2018, 2017 and 2016:

	Year ended December 31,
	2018			2017			2016

Dividend yield (%)		0			0			0
Expected volatility of the share prices (%)		93%-95	%		89%-94	%		71%-94	%
Risk-free interest rate (%)		2.63-2.88			1.76-2.4			0.3
Share price	$	8.00		$	5.00		$	13.4

Stock Option Activity

Movement during the year:

	2018				2017
	Number of options		Weighted average exercise price		Number of options		Weighted average exercise price
			USD				USD

Outstanding at beginning of year		2,467,023		2.28		1,129,008		0.25
Granted during the year		751,977		5.60		1,338,015		3.99
Expired during the period		2,000		6.00		-		-
Exercised during the period		9,692		0.25		-		-
Forfeited during the year		9,692		0.25		-		-

Share options outstanding at end of year		3,197,616		3.07		2,467,023		2.28
Share options exercisable at end of year		1,705,256		1.21		1,379,075		0.60

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA (Tables)

12 Months Ended

Dec. 31, 2018

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA [Abstract]

Research and Development Expenses, Net

Research and development expenses, net:

	Year ended December 31,
	2018			2017			2016

Salaries and social benefits	$	5,016		$	3,795		$	2,774
Share-based payment		705			1,362			3,195
Subcontractors		12,695			9,617			8,150
Materials		3,610			1,677			2,232
Rent and maintenance		758			486			364
Travel and trade shows		728			346			507
Depreciation		195			142			124
Other		239			-			61
Less royalty bearing grants		(1,901	)		(2,407	)		(4,030	)
Reversal of grants received in prior years to related liability		-			-			5,718

Total research and development expenses, net	$	22,045		$	15,018		$	19,095

General and Administrative Expenses

General and administrative expenses:

	Year ended December 31,
	2018		2017		2016

Salaries and social benefits	$	4,788	$	1,870	$	924
Share-based payment		2,870		846		2,647
Professional services		2,818		1,467		843
Rent and maintenance		1,065		83		138
Other		58		206		62

Total general and administrative expenses	$	11,599	$	4,472	$	4,614

Finance Expenses

Finance expenses:

	Year ended December 31,
	2018		2017		2016

Revaluation of IIA liability	$	2,037	$	631	$	-
Revaluation of liabilities at fair value		17,600		-		-
Bank charges, interest expense and other fees		68		54		23
Foreign currency translation adjustments		554		33		132

Total finance expenses	$	20,259	$	718	$	155

Finance Income

Finance income:

	Year ended December 31,
	2018		2017		2016

Interest income	$	877	$	330	$	163
Revaluation of liabilities at fair value		-		845		805
Foreign currency translation adjustments	$	165		22		225

Total finance income	$	1,042	$	1,197	$	1,193

GENERAL (Details) - USD ($) $ / shares in Units, $ in Thousands		12 Months Ended
	Oct. 30, 2018	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Equity [Abstract]
Net proceeds from IPO		$ 47,479	$ 0	$ 0
Conversion of preferred shares (in shares)	(17,289,289)
Accumulated deficits		(169,213)	(116,282)
Cash flows from operating activities		$ (26,426)	$ (16,549)	$ (12,590)
Initial Public Offering [Member]
Equity [Abstract]
Ordinary shares sold (in shares)	6,250,000
Share price (in dollars per share)	$ 8
Net proceeds from IPO	$ 47,241
Issuance costs related to equity	$ 5,947
Underwriters [Member]
Equity [Abstract]
Ordinary shares sold (in shares)	398,368

SIGNIFICANT ACCOUNTING POLICIES (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Short-term deposits and restricted deposits [Abstract]

Restricted deposit

$ 150

$ 0

Impairment of non-financial assets [Abstract]

Impairment of non-financial assets

$ 0

Government investment grants [Abstract]

Discount rate on grants

28.00%

25.00%

Royalties paid with respect to grants received

$ 0

Grants approved

2,425

2,948

$ 4,264

Grant receivable

$ 0

$ 1,578

Machinery [Member]

Property and equipment [Abstract]

Annual depreciation rate

15.00%

Office Furniture and Equipment [Member] | Bottom of Range [Member]

Property and equipment [Abstract]

Annual depreciation rate

6.00%

Office Furniture and Equipment [Member] | Top of Range [Member]

Property and equipment [Abstract]

Annual depreciation rate

33.00%

Leasehold Improvements [Member]

Property and equipment [Abstract]

Annual depreciation rate

^[1]

[1]	Leasehold improvements are depreciated on a straight-line basis over the shorter of the lease term (including the extension option held by the Company and intended to be exercised) and the expected life of the improvement.

DISCLOSURE OF NEW STANDARDS IN THE PERIOD PRIOR TO THEIR ADOPTION (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016	Dec. 31, 2015
New Standards Prior to Adoption [Abstract]
Total assets	$ 65,164	$ 44,922
Equity	24,687	22,956	$ 10,963	$ 27,812
Finance expenses	20,259	718	155
Operating loss	(33,644)	(19,490)	$ (23,709)
Loss before taxes on income	(52,861)	$ (19,011)
IFRS 16 [Member]
New Standards Prior to Adoption [Abstract]
Total assets	7,523
Total liabilities	(7,523)
Equity	0
Lease expenses	(1,940)
Depreciation	1,928
Finance expenses	94
Operating loss	12
Loss before taxes on income	$ (82)

CASH AND CASH EQUIVALENTS (Details) - USD ($)
$ in Thousands

12 Months Ended

Dec. 31, 2018

Dec. 31, 2017

Dec. 31, 2016

Dec. 31, 2015

CASH AND CASH EQUIVALENTS [Abstract]

Cash for immediate withdrawal

$ 3,289

$ 3,316

Cash equivalents - short-term deposits

^[1]

36,983

18,009

Cash and cash equivalents

$ 40,272

$ 21,325

$ 18,059

$ 28,742

Average annual interest rate on short-term bank deposits

2.05%

1.05%

[1]	The cash equivalents are short-term bank deposits denominated in USD and bear interest at an average annual rate of 2.05% and 1.050% as of December 31, 2018 and 2017, respectively.

PROPERTY AND EQUIPMENT, NET (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Composition and movement [Abstract]
Property and equipment, beginning balance	$ 940
Additions	1,640	$ 402
Depreciation	269	162
Property and equipment, ending balance	2,311	940
Costs [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	3,616	3,214
Property and equipment, ending balance	5,256	3,616
Accumulated Depreciation [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	2,676	2,514
Property and equipment, ending balance	2,945	2,676
Machinery [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	623
Additions	973	279
Depreciation	195	125
Property and equipment, ending balance	1,401	623
Machinery [Member] \| Costs [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	2,181	1,902
Property and equipment, ending balance	3,154	2,181
Machinery [Member] \| Accumulated Depreciation [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	1,558	1,433
Property and equipment, ending balance	1,753	1,558
Office Furniture and Equipment [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	88
Additions	139	27
Depreciation	37	16
Property and equipment, ending balance	190	88
Office Furniture and Equipment [Member] \| Costs [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	396	369
Property and equipment, ending balance	535	396
Office Furniture and Equipment [Member] \| Accumulated Depreciation [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	308	292
Property and equipment, ending balance	345	308
Leasehold Improvements [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	182
Additions	107	49
Depreciation	37	21
Property and equipment, ending balance	252	182
Leasehold Improvements [Member] \| Costs [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	992	943
Property and equipment, ending balance	1,099	992
Leasehold Improvements [Member] \| Accumulated Depreciation [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	810	789
Property and equipment, ending balance	847	810
Project in Progress [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	47
Additions	421	47
Depreciation	0	0
Property and equipment, ending balance	468	47
Project in Progress [Member] \| Costs [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	47	0
Property and equipment, ending balance	468	47
Project in Progress [Member] \| Accumulated Depreciation [Member]
Composition and movement [Abstract]
Property and equipment, beginning balance	0	0
Property and equipment, ending balance	$ 0	$ 0

ACCRUED EXPENSES AND OTHER PAYABLES (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017
ACCRUED EXPENSES AND OTHER PAYABLES [Abstract]
Subcontractors accruals	$ 1,096	$ 468
Legal and consulting accruals	479	201
Other	257	0
Accrued expenses and other payables	$ 1,832	$ 669

LIABILITIES PRESENTED AT FAIR VALUE, Warrants to Purchase Preferred E-2 and F-2 Shares (Details) $ / shares in Units, $ in Thousands		1 Months Ended	12 Months Ended
	Jul. 09, 2017 USD ($) shares	Dec. 31, 2018 shares ₪ / shares	Dec. 31, 2018 shares ₪ / shares	Dec. 31, 2018 $ / shares	Dec. 31, 2017 ₪ / shares	Jul. 09, 2017 ₪ / shares	Jul. 09, 2017 $ / shares
Ordinary Shares [Member]
Warrants to purchase shares [Abstract]
Par value (in sheqel per share) \| ₪ / shares		₪ 0.01	₪ 0.01		₪ 0.01
Share price (in dollars per share) \| $ / shares				$ 6.72
Increase (decrease) through exercise of warrants (in shares) \| shares		293,489	4,323,978
Preferred E-2 Shares [Member]
Warrants to purchase shares [Abstract]
Par value (in sheqel per share) \| ₪ / shares		₪ 0.01	₪ 0.01		0.01
Preferred F1 Shares [Member]
Warrants to purchase shares [Abstract]
Issuance of series F-1 preferred shares, net of issuance costs (in shares) \| shares	4,274,363
Par value (in sheqel per share) \| ₪ / shares		0.01	0.01		0.01	₪ 0.01
Share price (in dollars per share) \| $ / shares							$ 9.44
Preferred F-2 Shares [Member]
Warrants to purchase shares [Abstract]
Par value (in sheqel per share) \| ₪ / shares		₪ 0.01	₪ 0.01		₪ 0.01
Proceeds from issuance of shares \| $	$ 40,350
Issuance costs related to equity \| $	585
Issuance costs related to warrants \| $	$ 216
Warrants [Member]
Warrants to purchase shares [Abstract]
Number of warrants exercised (in shares) \| shares		(607,044)
Warrants [Member] \| Preferred F-2 Shares [Member]
Warrants to purchase shares [Abstract]
Par value (in sheqel per share) \| ₪ / shares						₪ 0.01
Number of warrants granted (in shares) \| shares	2,564,619
Exercise price of warrants (in dollars per share) \| $ / shares							$ 11.33
Number of warrants exercised (in shares) \| shares			(2,564,619)

LIABILITIES PRESENTED AT FAIR VALUE, Warrants to Purchase Preferred Shares, Valuation Inputs (Details)	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
Ordinary Shares [Member]
Warrants to purchase preferred shares [Abstract]
Risk-free interest rate	2.50%
Expected volatility	80.00%
Expected life	3 years 6 months
Expected dividend yield	0.00%
Preferred F-2 Shares [Member]
Warrants to purchase preferred shares [Abstract]
Risk-free interest rate		1.50%
Expected volatility		90.00%
Expected life		4 years 6 months
Expected dividend yield		0.00%

LIABILITIES PRESENTED AT FAIR VALUE, Changes in the Fair Value of Warrants (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Changes in the fair value of warrants [Abstract]
Exercise of warrants	$ 0	$ 10,900	$ 0
Revaluation of financial derivatives	17,600	(1,061)	(805)
Level 3 [Member]
Changes in the fair value of warrants [Abstract]
Balance at beginning of period	10,300	461	1,266
Proceeds from issue of financial derivatives		10,900
Exercise of warrants	(3,851)
Revaluation of financial derivatives	17,600	(1,061)	(805)
Balance at end of period	24,049	10,300	461
Warrants E-2 [Member] \| Level 3 [Member]
Changes in the fair value of warrants [Abstract]
Balance at beginning of period	0	461	1,266
Proceeds from issue of financial derivatives		0
Exercise of warrants	0
Revaluation of financial derivatives	0	(461)	(805)
Balance at end of period	0	0	461
Warrants [Member] \| Ordinary Shares [Member] \| Level 3 [Member]
Changes in the fair value of warrants [Abstract]
Balance at beginning of period	10,300	0	0
Proceeds from issue of financial derivatives		10,900
Exercise of warrants	(3,851)
Revaluation of financial derivatives	17,600	(600)	0
Balance at end of period	$ 24,049	$ 10,300	$ 0

LIABILITIES PRESENTED AT FAIR VALUE, Significant Unobservable Inputs to Valuation (Details) - Preferred F-2 Shares [Member] - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017
10% Increase in Volatility [Member]
Sensitivity to changes in inputs [Abstract]
Gain (loss) from changes in inputs	$ 0	$ 720
10% Decrease in Volatility [Member]
Sensitivity to changes in inputs [Abstract]
Gain (loss) from changes in inputs	0	(750)
1% Increase in Discount Rate [Member]
Sensitivity to changes in inputs [Abstract]
Gain (loss) from changes in inputs	0	(1,040)
1% Decrease in Discount Rate [Member]
Sensitivity to changes in inputs [Abstract]
Gain (loss) from changes in inputs	$ 0	$ (1,290)

CONTINGENT LIABILITIES AND COMMITMENTS (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
Future minimum lease fees payable [Abstract]
Future minimum lease fees payable	$ 6,720
Contingent obligations to IIA	34,197
Contingent obligations to IIA, accrued interest	$ 4,916
Bottom of Range [Member]
Future minimum lease fees payable [Abstract]
Royalties on sale proceeds	3.00%
Top of Range [Member]
Future minimum lease fees payable [Abstract]
Royalties on sale proceeds	4.00%
Royalties on sale proceeds to grants received	100.00%
Office Buildings and Production Plant [Member] \| Bottom of Range [Member]
Future minimum lease fees payable [Abstract]
Leases term	1 year
Office Buildings and Production Plant [Member] \| Top of Range [Member]
Future minimum lease fees payable [Abstract]
Leases term	9 years
Vehicles [Member]
Future minimum lease fees payable [Abstract]
Fixed monthly fee under operating lease	$ 13
Vehicles [Member] \| Bottom of Range [Member]
Future minimum lease fees payable [Abstract]
Leases term	1 year
Vehicles [Member] \| Top of Range [Member]
Future minimum lease fees payable [Abstract]
Leases term	3 years
First year [Member]
Future minimum lease fees payable [Abstract]
Future minimum lease fees payable	$ 1,803
Second through Fifth Years [Member]
Future minimum lease fees payable [Abstract]
Future minimum lease fees payable	2,522
After Fifth Year [Member]
Future minimum lease fees payable [Abstract]
Future minimum lease fees payable	$ 2,395

SHAREHOLDERS' EQUITY (Details) - ₪ / shares	Dec. 31, 2018	Dec. 31, 2017	Jul. 09, 2017	Dec. 31, 2016	Dec. 31, 2015	Nov. 23, 2014
Ordinary Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	100,000,000	22,007,000
Issued (in shares)	24,930,736	549,990
Outstanding (in shares)	24,930,736	549,990
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Ordinary B Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	140,000
Issued (in shares)	0	139,908
Outstanding (in shares)	0	139,908
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Ordinary C Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	1,130,000				1,500,000
Issued (in shares)	0	0
Outstanding (in shares)	0	0
Par value (in sheqel per share)	₪ 0.01	₪ 0.01				₪ 0.01
Ordinary Shares [Member]
Composition of share capital [Abstract]
Authorized (in shares)	100,000,000	23,277,000
Issued (in shares)	24,930,736	689,898
Outstanding (in shares)	24,930,736	689,898		689,898	689,898
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred A Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	600,000
Issued (in shares)	0	600,000
Outstanding (in shares)	0	600,000
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred B Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	1,454,000
Issued (in shares)	0	1,453,846
Outstanding (in shares)	0	1,453,846
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred C Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	2,828,000
Issued (in shares)	0	2,827,430
Outstanding (in shares)	0	2,827,430
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred D Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	3,405,000
Issued (in shares)	0	3,404,314
Outstanding (in shares)	0	3,404,314
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred E-1 Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	572,000
Issued (in shares)	0	571,478
Outstanding (in shares)	0	571,478
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred E-2 Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	1,024,000
Issued (in shares)	0	1,023,312
Outstanding (in shares)	0	1,023,312
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Series Preferred F-1 Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	4,275,000
Issued (in shares)	0	4,274,363
Outstanding (in shares)	0	4,274,363
Par value (in sheqel per share)	₪ 0.01	₪ 0.01	₪ 0.01
Series Preferred F-2 Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	2,565,000
Issued (in shares)	0	0
Outstanding (in shares)	0	0
Par value (in sheqel per share)	₪ 0.01	₪ 0.01
Preferred Share [Member]
Composition of share capital [Abstract]
Authorized (in shares)	0	16,723,000
Issued (in shares)	0	14,154,743
Outstanding (in shares)	0	14,154,743		9,880,380	9,880,380
Par value (in sheqel per share)		₪ 0.01

SHARE-BASED PAYMENT, Share Option Plan (Details)	12 Months Ended
SHARE-BASED PAYMENT, Share Option Plan (Details)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($)	Dec. 31, 2016 USD ($)	Dec. 31, 2018 ₪ / shares	Dec. 31, 2017 ₪ / shares shares	Dec. 28, 2017 shares	Jun. 26, 2017 shares	Jan. 23, 2017 ₪ / shares shares	Nov. 23, 2014 ₪ / shares shares
Share option plan [Abstract]
Option vesting period	3 years
Fair value measurement of equity-settled share options [Abstract]
Dividend yield (%)	0.00%	0.00%	0.00%
Risk-free interest rate (%)			0.30%
Share price (in sheqel per share) \| $	$ 8.00	$ 5.00	$ 13.40
Bottom of Range [Member]
Share option plan [Abstract]
Weighted average grant-date fair value (in sheqel per share) \| $	$ 3.64
Fair value measurement of equity-settled share options [Abstract]
Expected volatility of the share prices (%)	93.00%	89.00%	71.00%
Risk-free interest rate (%)	2.63%	1.76%
Top of Range [Member]
Share option plan [Abstract]
Weighted average grant-date fair value (in sheqel per share) \| $	$ 5.85
Fair value measurement of equity-settled share options [Abstract]
Expected volatility of the share prices (%)	95.00%	94.00%	94.00%
Risk-free interest rate (%)	2.88%	2.40%
Ordinary C Share [Member]
Share option plan [Abstract]
Par value (in sheqel per share) \| ₪ / shares				₪ 0.01	₪ 0.01				₪ 0.01
Authorized (in shares)	0				1,130,000				1,500,000
Shares issued (in shares)	0				0
Ordinary Shares [Member]
Share option plan [Abstract]
Par value (in sheqel per share) \| ₪ / shares				₪ 0.01	₪ 0.01
Authorized (in shares)	100,000,000				23,277,000
Shares issued (in shares)	24,930,736				689,898
2014 Plan [Member] \| Ordinary C Share [Member]
Share option plan [Abstract]
Shares issued (in shares)									1,152,044
2017 Plan [Member] \| Ordinary Shares [Member]
Share option plan [Abstract]
Par value (in sheqel per share) \| ₪ / shares								₪ 0.01
Number of shares reserved for issuance (in shares)	1,338,015					559,764	463,384	312,867

SHARE-BASED PAYMENT, Stock Option Activity (Details)	12 Months Ended
SHARE-BASED PAYMENT, Stock Option Activity (Details)	Dec. 31, 2018 USD ($) shares	Dec. 31, 2017 USD ($) shares
Number of Options [Abstract]
Outstanding at beginning of year (in shares) \| shares	2,467,023	1,129,008
Granted during the year (in shares) \| shares	751,977	1,338,015
Expired during the period (in shares) \| shares	2,000	0
Exercised during the period (in shares) \| shares	9,692	0
Forfeited during the year (in shares) \| shares	9,692	0
Share options outstanding at end of year (in shares) \| shares	3,197,616	2,467,023
Share options exercisable at end of year (in shares) \| shares	1,705,256	1,379,075
Weighted Average Exercise Price [Abstract]
Outstanding at beginning of year (in dollars per share) \| $	$ 2.28	$ 0.25
Granted during the year (in dollars per share) \| $	5.60	3.99
Expired during the period (in dollars per share) \| $	6.00	0
Exercised during the period (in dollars per share) \| $	0.25	0
Forfeited during the year (in dollars per share) \| $	0.25	0
Share options outstanding at end of year (in dollars per share) \| $	3.07	2.28
Share options exercisable at end of year (in dollars per share) \| $	$ 1.21	$ 0.60

TAXES ON INCOME (Details) - USD ($) $ in Thousands	12 Months Ended
TAXES ON INCOME (Details) - USD ($) $ in Thousands	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Corporate tax rates [Abstract]
Corporate tax rate	23.00%	24.00%	25.00%
Losses carryforward [Abstract]
Net operating losses	$ 120,000
Capital loss	500
Deferred taxes [Abstract]
Deferred tax assets	$ 0	$ 0
Development Area A [Member]
Corporate tax rates [Abstract]
Corporate tax rate	7.50%		9.00%
Other Regions [Member]
Corporate tax rates [Abstract]
Corporate tax rate	16.00%

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA, Research and Development Expenses, Net (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Research and development expenses, net [Abstract]
Salaries and social benefits	$ 5,016	$ 3,795	$ 2,774
Share-based payment	705	1,362	3,195
Subcontractors	12,695	9,617	8,150
Materials	3,610	1,677	2,232
Rent and maintenance	758	486	364
Travel and trade shows	728	346	507
Depreciation	195	142	124
Other	239	0	61
Less royalty bearing grants	(1,901)	(2,407)	(4,030)
Reversal of grants received in prior years to related liability	0	0	5,718
Total research and development expenses, net	$ 22,045	$ 15,018	$ 19,095

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA, General and Administrative Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
General and administrative expenses [Abstract]
Salaries and social benefits	$ 4,788	$ 1,870	$ 924
Share-based payment	2,870	846	2,647
Professional services	2,818	1,467	843
Rent and maintenance	1,065	83	138
Other	58	206	62
Total general and administrative expenses	$ 11,599	$ 4,472	$ 4,614

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA, Finance Expenses (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finance expenses [Abstract]
Revaluation of IIA liability	$ 2,037	$ 631	$ 0
Revaluation of liabilities at fair value	17,600	0	0
Bank charges, interest expense and other fees	68	54	23
Foreign currency translation adjustments	554	33	132
Total finance expenses	$ 20,259	$ 718	$ 155

SELECTED STATEMENTS OF COMPREHENSIVE LOSS DATA, Finance Income (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
Finance income [Abstract]
Interest income	$ 877	$ 330	$ 163
Revaluation of liabilities at fair value	0	845	805
Foreign currency translation adjustments	165	22	225
Total finance income	$ 1,042	$ 1,197	$ 1,193

RELATED PARTY TRANSACTIONS (Details) - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2018	Dec. 31, 2017	Dec. 31, 2016
RELATED PARTY TRANSACTIONS [Abstract]
Short-term benefits	$ 1,921	$ 1,578	$ 987
Other long-term benefits	63	569	61
Share-based payment	2,342	1,689	4,842
Key management personnel compensation	$ 4,326	$ 3,836	$ 5,890

SHARE-BASED PAYMENT, Unrecognized Company Cost (Details) $ in Thousands	12 Months Ended
	Dec. 31, 2018 USD ($)
SHARE-BASED PAYMENT [Abstract]
Total unrecognized cost	$ 4,103
Unrecognized company cost related to non-vested share based compensation expected to be recognized	4 years